Currently, drugs from natural sources that specifically inhibit peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT enhancer-binding protein alpha (C/EBPα) expression are being targeted for the treatment of obesity [9]. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.